Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
Status:
Withdrawn
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a treatment with Lenalidomide, which is a pill given
by mouth for 7.5 months (30 weeks total), can delay the growth of lymphoma or shrink the
lymphoma. Lenalidomide is a pill that has been approved by the Food and Drug Administration
(FDA). It is used to treat some forms of cancer-like illnesses (myelodysplastic syndrome
(MDS)and in combination with dexamethasone for patients with multiple myeloma (MM) who have
received at least 1 prior therapy. MDS and MM are cancers of the blood). This drug works by
stimulating the body's immune system and by reducing the blood supply to cancer cells. Cancer
cells need blood to live and grow. In this study, the drug is considered a new or
experimental drug because we are learning how it works against your form of lymphoma.